Neuroleptic malignant syndrome.
Pearlman
C
C
D014150:Antipsychotic Agents / Q000009:adverse effects*; D003342:Corpus Striatum / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D009459:Neuroleptic Malignant Syndrome / Q000503:physiopathology*; D011954:Receptors, Dopamine / Q000187:drug effects* / Q000502:physiology; D017448:Receptors, Dopamine D2; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects / Q000502:physiology; D013787:Thalamic Nuclei / Q000187:drug effects* / Q000503:physiopathology
D014150:Antipsychotic Agents; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D016194:Receptors, N-Methyl-D-Aspartate